145 related articles for article (PubMed ID: 18611902)
1. New insights into molecular mechanisms of haematological malignancies.
Fey MF
Ann Oncol; 2008 Jul; 19 Suppl 5():v59-62. PubMed ID: 18611902
[No Abstract] [Full Text] [Related]
2. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies.
Dimartino JF; Cleary ML
Br J Haematol; 1999 Sep; 106(3):614-26. PubMed ID: 10468849
[No Abstract] [Full Text] [Related]
3. DNMT3A in haematological malignancies.
Yang L; Rau R; Goodell MA
Nat Rev Cancer; 2015 Mar; 15(3):152-65. PubMed ID: 25693834
[TBL] [Abstract][Full Text] [Related]
4. Oligo-based High-resolution aCGH Analysis Enhances Routine Cytogenetic Diagnostics in Haematological Malignancies.
Kjeldsen E
Cancer Genomics Proteomics; 2015; 12(6):301-37. PubMed ID: 26543079
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in myeloid malignancies.
Gordon JE; Wong JJ; Rasko JE
Br J Haematol; 2013 Jul; 162(2):162-76. PubMed ID: 23679825
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and cytogenetic features of hematologic malignancies associated with acquired trisomy 21].
Wang H; Ni W; Chen Z; Lou J; Xu H; Yu Y; Qian W; Jin J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):576-8. PubMed ID: 18841576
[TBL] [Abstract][Full Text] [Related]
7. 7q22 deletion in myeloid malignancies: be attentive to the design of the FISH probe.
Struski S; Luquet I
Ann Biol Clin (Paris); 2019 Apr; 77(2):229-230. PubMed ID: 30907375
[No Abstract] [Full Text] [Related]
8. Genetics of myeloid malignancies: pathogenetic and clinical implications.
Fröhling S; Scholl C; Gilliland DG; Levine RL
J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms.
Kuo FC
Surg Pathol Clin; 2016 Sep; 9(3):475-88. PubMed ID: 27523973
[TBL] [Abstract][Full Text] [Related]
10. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
11. Molecular cytogenetic aspects of hematological malignancies: clinical implications.
Chen Z; Sandberg AA
Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693
[TBL] [Abstract][Full Text] [Related]
12. Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.
Lim TL; Lieberman DB; Davis AR; Loren AW; Hausler R; Bigdeli A; Li Y; Powers J; Raper A; Regeneron Genetics Center ; Carty SA; Nathanson KL; Bagg A; Hexner EO; Maxwell KN; Morrissette JJD; Babushok DV
Leukemia; 2022 Jan; 36(1):283-287. PubMed ID: 34193977
[No Abstract] [Full Text] [Related]
13. Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization.
Nebral K; König M; Schmidt HH; Lutz D; Sperr WR; Kalwak K; Brugger S; Dworzak MN; Haas OA; Strehl S
Haematologica; 2005 Jun; 90(6):746-52. PubMed ID: 15951287
[TBL] [Abstract][Full Text] [Related]
14. Secondary haematological malignancies in the BCIRG 001 study.
Arslan C; Uslu R
Lancet Oncol; 2013 Mar; 14(3):e87-8. PubMed ID: 23452357
[No Abstract] [Full Text] [Related]
15. Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
Gifford G; Wong K; Kerridge I; Stevenson W; Arthur C; Fay K; Greenwood M
Am J Hematol; 2015 May; 90(5):E97-100. PubMed ID: 25683457
[No Abstract] [Full Text] [Related]
16. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W
Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671
[TBL] [Abstract][Full Text] [Related]
17. [Chromosome analysis].
Miura I
Nihon Rinsho; 2012 Apr; 70 Suppl 2():181-7. PubMed ID: 23133949
[No Abstract] [Full Text] [Related]
18. Myeloid Neoplasm With Germline Predisposition: A 2016 Update for Pathologists.
Gao J; Gong S; Chen YH
Arch Pathol Lab Med; 2019 Jan; 143(1):13-22. PubMed ID: 29372845
[TBL] [Abstract][Full Text] [Related]
19. From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.
Jakobsen NA; Vyas P
Clin Med (Lond); 2018 Apr; 18(Suppl 2):s47-s53. PubMed ID: 29700093
[TBL] [Abstract][Full Text] [Related]
20. The proportion of clonal divisions varies in different hematologic malignancies. The United Kingdom Cancer Cytogenetics Group (UKCCG) [corrected].
Swansbury GJ
Cancer Genet Cytogenet; 1998 Jul; 104(2):139-45. PubMed ID: 9666808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
